Volker Heinemann
#116,657
Most Influential Person Now
Researcher
Volker Heinemann's AcademicInfluence.com Rankings
Volker Heinemanncomputer-science Degrees
Computer Science
#4571
World Rank
#4823
Historical Rank
Machine Learning
#942
World Rank
#956
Historical Rank
Artificial Intelligence
#1161
World Rank
#1182
Historical Rank
Database
#1786
World Rank
#1872
Historical Rank
Download Badge
Computer Science
Volker Heinemann's Degrees
- Masters Artificial Intelligence Technical University of Munich
Similar Degrees You Can Earn
Why Is Volker Heinemann Influential?
(Suggest an Edit or Addition)Volker Heinemann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. (2014) (1404)
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial (2019) (1012)
- Gemcitabine: metabolism, mechanisms of action, and self-potentiation. (1995) (737)
- Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. (2006) (648)
- Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (646)
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017) (577)
- Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. (1988) (538)
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017) (532)
- The Liver Tumor Segmentation Benchmark (LiTS) (2019) (447)
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer (2008) (428)
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. (2017) (414)
- Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. (1990) (405)
- Addressing the challenges of pancreatic cancer: future directions for improving outcomes. (2015) (383)
- Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (2016) (371)
- Advances in cancer immunotherapy 2019 – latest trends (2019) (339)
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. (2014) (337)
- Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier (2007) (336)
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. (2010) (334)
- Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. (1992) (327)
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. (2016) (312)
- [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. (2011) (287)
- Automatic Liver and Tumor Segmentation of CT and MRI Volumes using Cascaded Fully Convolutional Neural Networks (2017) (273)
- SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. (2016) (269)
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015) (243)
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials (2017) (240)
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials (2017) (240)
- Third consensus on medical treatment of metastatic breast cancer. (2007) (219)
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (216)
- Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. (2009) (213)
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer (2010) (177)
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group (2016) (172)
- Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030 (2016) (172)
- Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. (2000) (170)
- Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. (1999) (168)
- Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer (2006) (166)
- S3-Leitlinie zum exokrinen Pankreaskarzinom (2013) (161)
- [S3-guideline exocrine pancreatic cancer]. (2013) (158)
- Gemcitabine: Progress in the Treatment of Pancreatic Cancer (2000) (151)
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer (2012) (146)
- Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. (2006) (145)
- Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. (2013) (143)
- Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). (2015) (142)
- Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. (2007) (139)
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma (2020) (139)
- Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. (2008) (136)
- Clinical Relevance of Circulating Nucleosomes in Cancer (2008) (132)
- Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy (2013) (131)
- Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. (2007) (130)
- Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. (2013) (123)
- Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. (2014) (117)
- Systemic treatment of advanced pancreatic cancer. (2012) (116)
- Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. (2014) (112)
- Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. (2013) (111)
- FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). (2019) (111)
- [S3-Guidelines "Exocrine pancreatic cancer" 2007]. (2007) (109)
- Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. (2011) (108)
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) (2012) (106)
- Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. (2016) (106)
- Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. (2017) (105)
- Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. (2014) (104)
- S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). (2010) (104)
- Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. (2015) (104)
- Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial (2014) (103)
- [Update S3-guideline "colorectal cancer" 2008]. (2008) (101)
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. (2012) (99)
- An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine (2004) (98)
- Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer (2018) (98)
- Gilbert's Syndrome and Irinotecan Toxicity: Combination with UDP-Glucuronosyltransferase 1A7 Variants Increases Risk (2008) (92)
- Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). (2013) (91)
- Role of Gemcitabine in the Treatment of Advanced and Metastatic Breast Cancer (2003) (90)
- 2′,2′-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells (1989) (90)
- NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response predominantly in patients with intestinal type tumors (2015) (90)
- Anticancer therapy induced cardiotoxicity: review of the literature (2010) (89)
- 18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast Cancer (2012) (89)
- EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 (2012) (89)
- Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. (2009) (89)
- Risk factors for surgical complications in distal pancreatectomy. (2010) (88)
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer (2017) (87)
- Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients (1997) (86)
- Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. (1995) (86)
- Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. (2017) (86)
- Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial (2019) (84)
- Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. (2015) (83)
- Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial (2015) (83)
- Second consensus on medical treatment of metastatic breast cancer. (2007) (83)
- Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project (2018) (82)
- Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. (2008) (81)
- Validation of Several SUV-Based Parameters Derived from 18F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer (2013) (80)
- 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres (2011) (79)
- Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer (2006) (77)
- Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. (2013) (77)
- Cetuximab in the treatment of metastatic colorectal cancer (2007) (76)
- Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. (2006) (75)
- The Role of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer: Systematic Review of Randomized Controlled Trials and Meta-Analysis (2008) (74)
- Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. (2002) (74)
- Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. (2008) (74)
- Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin? (2003) (74)
- Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients (1994) (72)
- Importance of performance status for treatment outcome in advanced pancreatic cancer. (2007) (70)
- Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC) (2005) (69)
- KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer (2013) (67)
- Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy (2013) (67)
- Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase (2015) (66)
- Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. (2005) (66)
- LBA11INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION (2014) (65)
- Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. (2008) (63)
- Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. (2018) (63)
- Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials (2012) (63)
- The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. (2007) (62)
- CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. (1999) (62)
- Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial (2013) (60)
- Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study (2009) (57)
- Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. (2001) (57)
- Effect of Chemoradiotherapy with Gemcitabine and Cisplatin on Locoregional Control in Patients with Primary Inoperable Pancreatic Cancer (2004) (57)
- Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer (2013) (57)
- Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer (2008) (57)
- Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients. (2015) (56)
- Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy (2013) (56)
- A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. (2016) (56)
- Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. (2015) (55)
- Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group (2013) (55)
- Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer (2017) (55)
- Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. (2014) (54)
- Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer (2017) (53)
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial (2021) (53)
- Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases (2013) (53)
- Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trial (2013) (53)
- Present and future treatment of pancreatic cancer. (2002) (53)
- HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group. (2014) (51)
- Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. (2016) (50)
- mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109). (2017) (50)
- Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. (2019) (50)
- Gemcitabine-based combination treatment of pancreatic cancer. (2002) (50)
- MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). (2016) (49)
- Testicular biopsy for early cancer detection--objectives, technique and controversies. (2011) (49)
- Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer (2010) (49)
- Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. (2014) (49)
- Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? (2020) (49)
- Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. (2006) (49)
- Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. (2018) (49)
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. (2020) (48)
- FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial (2020) (48)
- F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor Markers (2007) (48)
- Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. (2007) (48)
- Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors. (2015) (48)
- How harmful is contralateral testicular biopsy?--an analysis of serial imaging studies and a prospective evaluation of surgical complications. (2005) (47)
- Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. (2014) (47)
- The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial (2012) (46)
- UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. (2009) (46)
- Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. (2011) (46)
- Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial (2019) (46)
- Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment) (2014) (45)
- Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status (2011) (44)
- Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors (2013) (44)
- Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer (2013) (43)
- Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. (2002) (43)
- HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). (2020) (43)
- Primary advanced unresectable pancreatic cancer. (2008) (43)
- Gemcitabine in metastatic breast cancer (2005) (42)
- Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. (1994) (42)
- Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients (1995) (42)
- Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306) (2017) (41)
- High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer (2006) (41)
- Preoperative serum markers for individual patient prognosis in stage I–III colon cancer (2015) (41)
- Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. (2010) (41)
- Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. (2015) (41)
- Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer (2014) (40)
- Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer (2010) (40)
- Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial (2017) (40)
- Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. (2013) (40)
- Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. (2017) (39)
- Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. (2013) (38)
- Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. (1989) (38)
- Perioperative management of pancreatic cancer. (2008) (38)
- SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 {+/-} bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) {+/-} bev in patients (pts) with metastatic colorectal cancer (mCRC). (2015) (37)
- Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. (2010) (37)
- Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer (2012) (37)
- Economic evaluation of genetic screening for Lynch syndrome in Germany (2015) (37)
- Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. (2019) (37)
- Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. (2016) (36)
- UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? (2009) (36)
- A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development (2020) (35)
- Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. (2004) (35)
- Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. (2016) (35)
- Oligometastatic Disease in Pancreatic Cancer - How to Proceed (2017) (34)
- Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial. (2014) (34)
- New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin (2016) (34)
- Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. (2014) (34)
- Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. (2006) (33)
- [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective]. (2003) (33)
- Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients. (2010) (33)
- Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. (1989) (33)
- Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. (2019) (33)
- Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity (2011) (33)
- Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer (2018) (33)
- Resection of Pulmonary Metastases from Colon and Rectal Cancer: Factors to Predict Survival Differ Regarding to the Origin of the Primary Tumor (2014) (33)
- Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer (2011) (32)
- Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. (2017) (32)
- Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. (2016) (32)
- Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (2010) (32)
- Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial) (2016) (31)
- Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives (2016) (31)
- Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110). (2019) (31)
- Radiosurgery of Liver Tumors: Value of Robotic Radiosurgical Device to Treat Liver Tumors (2010) (29)
- Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. (2015) (29)
- How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials (2017) (29)
- Gastrointestinal toxicity associated with weekly docetaxel treatment. (2002) (29)
- Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2010) (29)
- A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. (2011) (29)
- Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. (2014) (28)
- Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study. (2006) (28)
- Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. (2018) (28)
- Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer (2008) (28)
- Sinnvoller Einsatz von Tumormarkern / Sensible use of tumor markers (2008) (28)
- Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. (2012) (28)
- CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). (2016) (27)
- Leukapheresis in Chronic Myelomonocytic Leukemia with Leukostasis Syndrome: Elevated Serum Lactate Levels as an Early Sign of Microcirculation Failure (2002) (27)
- Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. (2008) (27)
- Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine (1999) (27)
- Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (2018) (27)
- Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC) (2011) (27)
- Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation (1997) (26)
- Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial (2011) (26)
- pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 (2014) (26)
- Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial (2019) (25)
- Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors (2021) (25)
- The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance (2016) (25)
- Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. (2006) (25)
- 18 F-FDG PET / CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast Cancer (2012) (24)
- High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. (2005) (24)
- Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies (2018) (24)
- A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer (2009) (24)
- Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials (2012) (24)
- Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer (2011) (24)
- Ductal pancreatic adenocarcinoma. (2014) (24)
- Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer (2013) (23)
- Weekly Irinotecan in a Patient with Metastatic Colorectal Cancer on Hemodialysis due to Chronic Renal Failure (2002) (23)
- The relevance of CT-based geometric and radiomics analysis of whole liver tumor burden to predict survival of patients with metastatic colorectal cancer (2020) (23)
- O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) (2014) (23)
- Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. (1990) (23)
- New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. (1991) (23)
- Radiochemotherapie mit Gemcitabin und Cisplatin bei Pankreaskarzinom – durchführbar und effektiv (2003) (23)
- Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. (1991) (22)
- Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. (2007) (22)
- Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma (2016) (22)
- Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial (2013) (22)
- Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer (2010) (22)
- Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. (2017) (22)
- Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer (2017) (22)
- Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005 (2011) (22)
- Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (2017) (21)
- Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. (2005) (21)
- Factors associated with the decline of psychological support in hospitalized patients with cancer (2019) (21)
- Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy (2020) (21)
- The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. (2009) (21)
- Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). (2021) (20)
- Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials (2015) (20)
- 1376O The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial) (2021) (20)
- O-0009QUANTITATIVE ANALYSIS OF THE IMPACT OF DEEPNESS OF RESPONSE ON POST-PROGRESSION SURVIVAL TIME FOLLOWING FIRST-LINE TREATMENT IN PATIENTS WITH MCRC (2013) (20)
- Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score (2021) (20)
- Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. (2015) (19)
- Predictive value of TLR7 polymorphism for cetuximab‐based chemotherapy in patients with metastatic colorectal cancer (2017) (19)
- Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer (2016) (19)
- Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany? (2020) (19)
- Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. (1997) (19)
- RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients (2006) (19)
- Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. (2014) (19)
- Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. (2016) (19)
- A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab (2017) (19)
- Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials (2017) (18)
- The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. (2008) (18)
- Surgical treatment concepts for patients with pancreatic cancer in Germany—results from a national survey conducted among members of the “Chirurgische Arbeitsgemeinschaft Onkologie” (CAO) and the “Arbeitsgemeinschaft Internistische Onkologie” (AIO) of the Germany Cancer Society (DKG) (2011) (18)
- Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy (2014) (18)
- Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. (2007) (18)
- Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group (2008) (17)
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. (2011) (17)
- Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. (2020) (17)
- The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy (2017) (17)
- Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). (2010) (17)
- Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society (2009) (17)
- Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212) (2021) (17)
- Serum pharmacology of amphotericin B applied in lipid emulsions (1997) (17)
- Therapie schwerer akneiformer Cetuximab-Exantheme mit oralem Retinoid, topischem Antibiotikum und Steroidexternum (2007) (17)
- Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. (2007) (17)
- Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis (2012) (16)
- MiR 31 3p as a predictive biomarker of cetuximab efficacy effect in metastatic colorectal cancer (mCRC) patients enrolled in FIRE-3 study. (2016) (16)
- LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial (2012) (16)
- Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). (2020) (16)
- Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? (2007) (16)
- Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. (2005) (16)
- Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. (2014) (16)
- High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer (2005) (16)
- Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial (2017) (16)
- KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer (2013) (16)
- Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. (2013) (16)
- Effective Second-Line Treatment with Cetuximab and Bevacizumab in a Patient with Hepatic Metastases of Colorectal Cancer and Hyperbilirubinemia (2007) (16)
- A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer (2012) (15)
- Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta- analysis of sixteen randomized trials (2007) (15)
- Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306) (2017) (15)
- Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. (2010) (15)
- Combined resection of colorectal hepatic–pulmonary metastases shows improved outcome over chemotherapy alone (2013) (15)
- Testicular microlithiasisOne case and four points to note (2003) (15)
- Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials (2015) (15)
- Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). (2019) (15)
- Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial (2005) (14)
- The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
- Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer (2017) (14)
- Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study (2014) (14)
- Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer (2005) (14)
- Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (2018) (14)
- Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival (2020) (14)
- Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group. (2006) (14)
- Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer (2018) (13)
- Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. (2014) (13)
- Leopard-like vitiligo with capecitabine (2001) (13)
- Interventionell-radiologische perkutane Implantation intravenöser Port-Katheter-Systeme (1999) (13)
- Web-/APP-based connected care solution for COVID-19 in- and outpatient care. (2020) (13)
- The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer (2018) (13)
- Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. (2017) (13)
- Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
- Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels (2013) (13)
- [Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]. (2007) (13)
- Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment. (2013) (13)
- Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases. (2012) (13)
- PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors (2017) (12)
- Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer. (2008) (12)
- Universal Genomic Testing: The next step in oncological decision-making or a dead end street? (2017) (12)
- O-0029FOLFIRI PLUS CETUXIMAB VERSUS FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF KRAS-WILDTYPE METASTATIC COLORECTAL CANCER: GERMAN AIO STUDY KRK-0306 (FIRE-3) (2013) (12)
- Cancer patients' expectations when undergoing extensive molecular diagnostics—A qualitative study (2019) (12)
- POLE gene hotspot mutations in advanced pancreatic cancer (2018) (12)
- FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply. (2014) (12)
- Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. (2008) (12)
- Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3 (2015) (12)
- Reduced Periprocedural Analgesia After Replacement of Water for Injection with Glucose 5% Solution as the Infusion Medium for 90Y-Resin Microspheres (2016) (12)
- Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). (2019) (12)
- A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial (2011) (12)
- Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. (2018) (12)
- Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC). (2014) (12)
- Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials (2020) (12)
- Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306 (2020) (11)
- Prognostic Effect of Adenosine‐related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab‐based Chemotherapy (2019) (11)
- Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial. (2012) (11)
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
- Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial (2018) (11)
- Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. (2020) (11)
- Acute myeloid leukemia in the elderly: biological features and search for adequate treatment (1991) (11)
- Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. (2013) (11)
- Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. (2019) (11)
- Predicting Lesion Growth and Patient Survival in Colorectal Cancer Patients using Deep Neural Networks (2018) (11)
- CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial (2018) (11)
- Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases (2018) (11)
- BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. (2021) (10)
- Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer (2008) (10)
- Interventional Antimicrobial Therapy in Febrile Neutropenic Patients (PEG Study II) (1998) (10)
- The Technome - A Predictive Internal Calibration Approach for Quantitative Imaging Biomarker Research (2020) (10)
- KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. (2015) (10)
- Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. (2021) (10)
- Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash (2017) (10)
- Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease (2018) (10)
- Molecular subtyping of gastric cancer with respect to the growth pattern of lymph-node metastases (2019) (10)
- Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer (2010) (10)
- Comment on "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". (2022) (10)
- Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib (2015) (10)
- Tumor markers in metastatic breast cancer: High tumor specificity within the reference range. (2006) (10)
- HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors. (2012) (10)
- Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board (2022) (10)
- Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine (1988) (10)
- Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? (2010) (10)
- Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox (2019) (9)
- S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL (2022) (9)
- Percutaneous CT fluoroscopy-guided core biopsy of pancreatic lesions: technical and clinical outcome of 104 procedures during a 10-year period (2017) (9)
- [Interdisciplinary diagnosis of and therapy for cholangiocarcinoma]. (2008) (9)
- Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts (2019) (9)
- Single nucleotide polymorphisms in the IGF‐IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE‐3 trial (2017) (9)
- Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer (2011) (9)
- Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers. (2020) (9)
- Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival (2005) (9)
- Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. (2009) (9)
- 1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109). (2018) (9)
- NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU (2020) (9)
- Clinical picture: leopard-like vitiligo with capecitabine. (2001) (9)
- Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). (2012) (9)
- Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab (2016) (9)
- Re-Evaluation of HER2 Status in Metastatic Breast Cancer and Tumor-Marker Guided Therapy with Vinorelbine and Trastuzumab (2005) (9)
- Standards and Challenges of Care for Colorectal Cancer Today (2016) (9)
- High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. (2015) (9)
- Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group. (2014) (9)
- Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy. (2013) (8)
- How can CEA and CA15-3 be used for estimation of the clinical status and effectiveness of therapy during metastatic breast cancer? (2004) (8)
- [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid]. (2007) (8)
- Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (2015) (8)
- Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients. (2013) (8)
- A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. (2020) (8)
- Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC). (2019) (8)
- Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. (2011) (8)
- Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials (2020) (8)
- Potential role of PIN1 genotypes in predicting benefit from oxaliplatin- and irinotecan-based treatment in patients with metastatic colorectal cancer (2018) (8)
- Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial. (2011) (8)
- Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306). (2018) (8)
- Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306). (2017) (7)
- Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment (2020) (7)
- Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104 (2015) (7)
- Anti-epidermal growth factor receptor treatment strategies in advanced pancreatic cancer: success or failure? (2011) (7)
- Activity and tolerability of gemcitabine plus cisplatin in advanced metastatic pancreatic carcinoma (1997) (7)
- [Percutaneous interventional radiologic implantation of intravenous port-catheter systems]. (1999) (7)
- Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. (1990) (7)
- Cetuximab-related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with molecular markers: Results from the German AIO CRC 0104 trial. (2012) (7)
- Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC) (2020) (7)
- Capecitabine as Second-Line Treatment for Metastatic Cholangiocarcinoma: A Report of Two Cases (2002) (7)
- A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results. (2012) (7)
- Improving post-surgical management of resected pancreatic cancer (2017) (7)
- Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study (2020) (7)
- Chirurgische Therapie des lokal fortgeschrittenen und primär inoperablen Pankreaskarzinoms nach neoadjuvanter präoperativer Radiochemotherapie (2002) (7)
- Review of bevacizumab in the treatment of metastatic breast cancer (2008) (7)
- Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer (2021) (7)
- Age and metastasis - How age influences metastatic spread in cancer. Colorectal cancer as a model. (2022) (7)
- Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS. (2012) (7)
- Predictive and prognostic biomarker models in advanced lung cancer (2008) (6)
- Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group (2008) (6)
- Translational research in pancreatic cancer: KRAS and beyond. (2014) (6)
- Präzisionsonkologie und molekulare Tumorboards – Konzepte, Chancen und Herausforderungen (2017) (6)
- Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer (2017) (6)
- Pharmacologically directed design of leukemia therapy. (1990) (6)
- Information, communication, and cancer patients’ trust in the physician: what challenges do we have to face in an era of precision cancer medicine? (2020) (6)
- Novel systemic treatment approaches for metastatic pancreatic cancer (2022) (6)
- Clonal hematopoiesis associates with improved survival in metastatic colorectal cancer patients from the FIRE-3 trial. (2021) (6)
- Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer. (2004) (6)
- Safety of palliative chemotherapy in advanced pancreatic cancer (2016) (6)
- Regional hyperthermia (RHT) combined with gemcitabine (GEM) + cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO phase II trial (2008) (6)
- HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer. (2009) (6)
- Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting (2021) (6)
- Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE‐3 (AIO KRK‐0306) (2021) (6)
- Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. (2020) (6)
- Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. (2021) (6)
- [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges]. (2017) (6)
- Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study (2022) (6)
- FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis (2017) (6)
- Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult (2014) (6)
- [Tumor markers--how they should be applied]. (2005) (6)
- Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study (2020) (6)
- 1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma (2020) (6)
- ALK expression is absent in pancreatic ductal adenocarcinoma (2014) (6)
- Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. (2020) (6)
- Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). (2017) (6)
- S3-Guideline “Exocrine Pancreatic Carcinoma” 20071 (2008) (6)
- Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results. (2014) (6)
- Frameless single robotic radiosurgery of pulmonary metastases in colorectal cancer patients. (2016) (5)
- Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer (2015) (5)
- Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final analysis of a phase I/II studay (2005) (5)
- O-0020OUTCOME ACCORDING TO TUMOR RAS MUTATION STATUS IN CRYSTAL STUDY PATIENTS WITH METASTATIC COLORECTAL CANCER RANDOMIZED TO FOLFIRI WITH OR WITHOUT CETUXIMAB AS FIRST-LINE TREATMENT (2014) (5)
- Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models (2021) (5)
- Partition: a surjective mapping approach for dimensionality reduction (2020) (5)
- Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine? (2021) (5)
- Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML). (1989) (5)
- Primary effusion lymphoma (PEL) without effusion: a patient case report of a PEL solid variant (2011) (5)
- Interventional radiological procedures in impaired function of surgically implanted catheter-port systems (2001) (5)
- NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients (2018) (5)
- The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab (2018) (5)
- Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. (2017) (5)
- Evaluating the agreement between the empirical volumes of tumor lesions and the estimated volumes of tumor lesions based on the longest diameter. (2012) (5)
- Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (2021) (5)
- Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial. (2014) (5)
- CA 125 in the early detection of metastatic breast cancer. (2009) (5)
- Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm (2014) (5)
- Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. (2019) (5)
- Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel (2021) (5)
- Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR) (2017) (5)
- Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) - a retrospective, central evaluation of FIRE-3 (2016) (5)
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine: Interim toxicity analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2009) (5)
- Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204). (2010) (5)
- Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). (2021) (5)
- Ductal Pancreatic Adenocarcinoma: Surgery, Pathology Work-up, and Neoadjuvant, Adjuvant, and Palliative Treatments (2014) (5)
- pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 (2013) (5)
- Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. (1995) (5)
- 528PAFLIBERCEPT + FOLFIRI FOR TREATMENT OF METASTATIC COLORECTAL CANCER AFTER OXALIPLATIN FAILURE: 4TH INTERIM SAFETY DATA FROM THE GLOBAL AFLIBERCEPT SAFETY AND QUALITY-OF-LIFE PROGRAM (ASQOP/AFEQT STUDIES). (2014) (5)
- Long-term survival with metastatic breast cancer (MBC): Results of a retrospective, single-centre analysis from 2000-2005 (2008) (5)
- Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database. (2016) (4)
- Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment of patients with locally advanced, nonmetastatic pancreatic cancer. (2016) (4)
- Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy. (2017) (4)
- A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials (2016) (4)
- Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (2016) (4)
- [Growth factors. A new dimension in understanding oncogenesis]. (1985) (4)
- Follow-Up for Breast Cancer – the Patients’ View (2006) (4)
- Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial). (2015) (4)
- [Neoadjuvant and adjuvant therapy of resectable colon cancer - Current standards and developments]. (2021) (4)
- Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE‐3 Study (2018) (4)
- Evaluation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial (2007) (4)
- Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer (2016) (4)
- Regulation of deoxycytidine kinase by deoxycytidine and deoxycytidine 5' triphosphate in whole leukemia and tumor cells. (1998) (4)
- Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study. (2017) (4)
- Das Optimult-Studienkonzept – Grundlage für selektiven Einsatz neoadjuvanter Radiochemotherapie auf MRT-Basis? (2010) (4)
- Neue Tyrosinkinase- und EGFR-Inhibitoren in der Tumortherapie (2011) (4)
- Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutations on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). (2014) (4)
- Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC). (2016) (4)
- LBA-006Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy. (2017) (4)
- Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE‐3) (2021) (4)
- S3-Leitlinie zum exokrinen S3-Guideline Exocrine Pancreatic Cancer (2013) (4)
- Pharmacologically directed design of aml therapy (1990) (4)
- Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3) (2021) (4)
- Neue Daten zum Pankreaskarzinom (2010) (4)
- Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. (2018) (4)
- BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. (2019) (3)
- Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years (2022) (3)
- Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC). (2019) (3)
- Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer (2019) (3)
- [Advanced radioiodine-refractory differentiated thyroid cancer]. (2015) (3)
- AmBisome® : pharmacokinetics and clinical results (1993) (3)
- [Locally advanced pancreatic carcinoma. Radiochemotherapy prolongs survival]. (2000) (3)
- Behandlung des fortgeschrittenen und metastasiertens (2005) (3)
- [The optimult study concept - selective neoadjuvant chemoradiation therapy based on preoperative MRI]. (2010) (3)
- Treatment options for patients with pretreated metastatic breast cancer. (2007) (3)
- Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal (2022) (3)
- Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21’s influence on gene expression in the EGFR signaling pathway. (2019) (3)
- [New data on pancreatic cancer]. (2010) (3)
- 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database (2020) (3)
- Second-line therapy with pemetrexed after gemcitabine failure in patients with unresectable locally advanced or metastatic pancreatic cancer: A multicenter phase II trial. (2006) (3)
- Germline polymorphisms (SNPs) to predict toxicity and efficacy in FLOT-treated patients with locally advanced gastroesophageal junction or gastric adenocarcinoma—data from the NeoFLOT study (2018) (3)
- Gemcitabine + cisplatin (GEM+CIS) in combination with regional hyperthermia (RHT) in second-line therapy of gemcitabine-refractory metastatic pancreatic cancer. (2006) (3)
- Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine. (1993) (3)
- The pattern of HER-2/neu release in benign and malignant diseases (2005) (3)
- Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. (2021) (3)
- Chemoradiation (CRT) with gemcitabine (G) in primarily inoperable pancreatic cancer (2001) (3)
- Analysis of prognostic factors in patients with advanced pancreatic cancer: Subgroup analysis of a randomized phase III trial comparing single-agent gemcitabine to the gemcitabine plus cisplatin combination (2005) (3)
- Complete pathological response to neoadjuvant pemetrexed/cisplatin in combination with regional hyperthermia in a patient with sarcomatoid peritoneal mesothelioma. (2014) (3)
- Definition of An Optimal First-line Chemotherapy in Metastatic Breast Cancer (2003) (3)
- Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212). (2021) (3)
- Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer (2020) (3)
- Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group (2008) (3)
- [Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy]. (2002) (3)
- Repeated blast crisis (BC) of changing morphology, immunologic phenotype and cytogenetics in chronic myeloid leukemia (CML). (1989) (3)
- Randomized phase II trial comparing gemcitabine/cisplatin-based chemoradiotherapy (CRT) to 5-FU-based CRT in patients with locally advanced pancreatic cancer. (2006) (3)
- The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials. (2021) (3)
- 508PD2ND-LINE THERAPIES AFTER 1ST-LINE THERAPY WITH FOLFIRI IN COMBINATION WITH CETUXIMAB OR BEVACIZUMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)-ANALYSIS OF THE AIO KRK 0306 (FIRE 3)- TRIAL. (2014) (3)
- Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. (2016) (3)
- Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall Survival. (2017) (3)
- Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma. (2012) (3)
- Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients (2022) (3)
- Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. (2018) (3)
- Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). (2020) (3)
- Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea. (1998) (3)
- Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). (2021) (3)
- Four testicular biopsies failing to detect a case of testicular intraepithelial neoplasia (2004) (3)
- [Chemotherapy of metastatic colorectal cancer]. (2014) (3)
- Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. (2020) (3)
- [Vitamins and Minerals in Oncology]. (2017) (2)
- Course of calcium and magnesium serum levels in cetuximab-treated patients: Relation to concurrent chemotherapy and possible predictive value. (2013) (2)
- Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer. (2012) (2)
- Lasting remission following multimodal treatment in a patient with metastatic breast cancer (2005) (2)
- Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. (2018) (2)
- Impact of gene promoter polymorphism of the UGT1A1-gene on the occurrance of irinotecan-induced side effects and drug effiacy (2005) (2)
- 506TiP Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study (2021) (2)
- Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer: A single-center study (2007) (2)
- Percutaneous radiofrequency ablation (RFA) of hepatic metastases in patients with metastatic breast cancer: An interim analysis. (2004) (2)
- 1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO (2022) (2)
- 18 F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated (2011) (2)
- [Metastatic colorectal cancer--analysis of treatment modalities and survival now and then]. (2014) (2)
- Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial (2007) (2)
- Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab. (2018) (2)
- Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon. (2016) (2)
- Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. (2015) (2)
- Role of CCL5 and CCR5 gene polymorphisms in EGFR signaling blockade in Metastatic Colorectal Cancer: Analysis of the FIRE-3 trial (2019) (2)
- Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study (2020) (2)
- Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis (2021) (2)
- Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine. (2014) (2)
- Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database. (2020) (2)
- Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers (2022) (2)
- ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors–An explorative randomized phase II trial. (2015) (2)
- Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study. (2018) (2)
- MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial (2016) (2)
- Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer (2022) (2)
- Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 (2022) (2)
- [Multimodality treatment concepts for metastatic breast cancer]. (2010) (2)
- Influence of mRNA expression of fibroblast growth factor 2 (FGF2) in colorectal cancer (CRC) cell lines and in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1). (2016) (2)
- Variations in Y chromosome-related genes and clinical outcome in metastatic colorectal cancer. (2015) (2)
- FIRE-6 Studie (2019) (2)
- Evaluation of Visualization Using a 50/50 (Contrast Media/Glucose 5% Solution) Technique for Radioembolization as an Alternative to a Standard Sandwich Technique (2017) (2)
- Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study (2020) (2)
- Reversal of P-glycoprotein related resistance by idarubicin (1993) (2)
- AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta‐analysis using TRIBE, MAVERICC and FIRE3 (2019) (2)
- Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials. (2021) (2)
- A phase II pilot trial with RP101 in advanced pancreatic carcinoma. (2006) (2)
- O-00182ND-LINE THERAPIES AFTER 1ST-LINE THERAPY WITH FOLFIRI IN COMBINATION WITH CETUXIMAB OR BEVACIZUMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)-ANALYSIS OF THE AIO KRK 0306 (FIRE 3)- TRIAL (2014) (2)
- [Neoadjuvant and adjuvant therapies for solid tumours]. (2007) (2)
- Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial. (2019) (2)
- TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells. (2014) (2)
- Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial. (2022) (2)
- Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients (2021) (2)
- Gemcitabine (Gemzar) and radiotherapy--is it feasible? (2002) (2)
- A double-blind, randomized, placebo-controlled, phase II study of maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following first-line therapy for metastatic colorectal cancer (mCRC). (2011) (2)
- The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer (2022) (2)
- Overall survival analysis of the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (2017) (2)
- Ongoing selective internal radiation therapy-based studies in the treatment of liver-dominant metastatic colorectal cancer. (2014) (2)
- Sym004: Truly a New Level of Anti-EGFR Treatment? (2015) (2)
- Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114). (2022) (2)
- External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy (2012) (2)
- Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). (2018) (2)
- Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. (2015) (2)
- Das fortgeschrittene Radioiod-refraktäre differenzierte Schilddrüsenkarzinom (2015) (2)
- Chemotherapie und Immuntherapie des metastasierten Mammakarzinoms (2002) (2)
- Duktales Adenokarzinom des Pankreas (2019) (2)
- Chemotherapie des metastasierten kolorektalen Karzinoms (2014) (2)
- Internistisch-onkologische Aspekte bei der Behandlung des Pankreaskarzinoms (2009) (2)
- Wissenschaftsbasierte Entwicklung von patientenorientierten Rezeptideen in der Onkologie (2020) (2)
- Randomized phase III study in advanced and metastatic pancreatic cancer: single-agent gemcitabine versus gemcitabine plus cisplatin (2001) (2)
- SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC) (2016) (1)
- Regional hyperthermia (RHT) as an innovative treatment component: RHT combined with gemcitabine (G) and cisplatin (CIS) in G-pretreated advanced pancreatic cancer (APC). (2011) (1)
- Systemtherapie des metastasierten Pankreaskarzinoms: Aktuelle Standards und Perspektiven (2019) (1)
- Repeated mutKRAS ctDNA measurements in patients with advanced pancreatic cancer patients: Kinetics, response prediction and therapy monitoring in comparison to protein-based tumor markers. (2018) (1)
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (2023) (1)
- Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models (2021) (1)
- Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). (2018) (1)
- PD-013A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC) (2015) (1)
- Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE. (2016) (1)
- Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3. (2018) (1)
- Nur der gezielte einsatz bringt vorteile für den patienten : Tumormarker gehören nicht zum routine-check-up (2005) (1)
- Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis (2018) (1)
- Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial. (2012) (1)
- Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial. (2011) (1)
- Isolated pulmonary metastases in pancreatic cancer: preliminary results from the retrospective multi-center AIO-YMO-PAK-0515 study (2017) (1)
- Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. (2022) (1)
- NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma. (2012) (1)
- Treatment of locoregional disease: adjuvant versus neoadjuvant. (2012) (1)
- Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer (2008) (1)
- Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL (2022) (1)
- O-019SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment (2015) (1)
- Randomisierte, doppelblinde, placebo-kontrollierte Phase III Multicenterstudie (CORRECT) von Regorafenib plus Best Supportive Care (BSC) versus Placebo plus BSC bei Patienten (Pat) mit metastasiertem kolorektalem Karzinom (mCRC), die nach einer Standardtherapie progredient waren (2012) (1)
- FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). (2021) (1)
- [Age factors in cancer therapy]. (2000) (1)
- Intermediate-Dose Arabinoside and Amsacrine: An Effective Regimen in Relapsed and Refractory Acute Leukemia (1992) (1)
- Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3. (2016) (1)
- Bendamustin bei B-Zell-Neoplasien und kleinzelligen Bronchialkarzinomen (2003) (1)
- Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]. (2022) (1)
- Nachbehandlung und Nachsorge entsprechend dem UICC-Stadium (2011) (1)
- Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO. (2019) (1)
- Molekulare Charakterisierung des Pankreaskarzinoms (2019) (1)
- P-0099 Two-Thirds of Pancreatic Ductal Adenocarcinomas have low Expression of Hent1 as Determined by the Sp120 Rabbit Monoclonal Antibody Immunohistochemistry Test (2012) (1)
- Effect of weight loss in patients with metastatic colorectal cancer treated within the randomized phase III FIRE-3 trial (AIO KRK 0306). (2020) (1)
- [Comparative study on the pharmacokinetics of various amphotericin B preparations]. (1994) (1)
- Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study. (2014) (1)
- Die Auswirkungen der COVID-19-Pandemie aus der Sicht ambulanter Krebspatienten (2022) (1)
- A still missing piece of the FIRE-3 puzzle - Authors' reply. (2016) (1)
- 2010 A genetic variant in RASSF1A, a key regulator of HIPPO pathway, predicts survival in two independent cohorts of mCRC patients treated with cetuximab-based chemotherapy (2015) (1)
- Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial. (2019) (1)
- Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. (2018) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104). (2013) (1)
- Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. (2017) (1)
- PD-027BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306) (2016) (1)
- Multimodale kurative/neoadjuvante Therapie beim Pankreaskarzinom (2004) (1)
- Vitamine und Spurenelemente in der Onkologie (2018) (1)
- 6597 Multicenter phase II trial of trastuzumab and capecitabine in patients with HER2 expressing metastasized pancreatic cancer (2009) (1)
- Early prediction of response to chemotherapy by circulating nucleosomes and CYFRA 21-1. (2004) (1)
- The prognostic importance of the CA19–9 tumour marker and its use as a biochemical indicator of treatment response during (chemo-) radiotherapy of locally advanced pancreatic cancer (2004) (1)
- Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours (2019) (1)
- Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306). (2014) (1)
- [Colon cancer: adjuvant chemotherapy and aftercare]. (2011) (1)
- [Carcinoma of head of pancreas: most common cause of obstructive jaundice]. (2009) (1)
- Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials. (2019) (1)
- MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. (2016) (1)
- Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC. (2012) (1)
- Gemcitabine plus carboplatin for patients with pretreated, metastatic breast cancer: A phase II trial. (2006) (1)
- Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study. (2019) (1)
- Application of a time-varying covariate model to the analysis of CA 19-9 as a biomarker for time-to-progression (TTP) and overall survival (OS) in patients with advanced pancreatic cancer. (2009) (1)
- Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial. (2020) (1)
- Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location. (2017) (1)
- A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonaïve advanced esophagogastric cancer (AEGC). (2015) (1)
- Relevant Diseases and Therapeutic Options (2008) (1)
- Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform exanthema caused by the EGFR-inhibitor cetuximab (2008) (1)
- Selective internal radiation therapy (SIRT) for treatment of patients with breast cancer with metastatic liver disease. (2010) (1)
- TLR6 polymorphism associated with overall survival in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI/bevacizumab enrolled in FIRE3. (2015) (1)
- Pattern of S 100-release in benign and malignant diseases beside malignant melanoma (2013) (1)
- Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX. (2017) (1)
- Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series. (2022) (1)
- [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin]. (2011) (1)
- [Metastatic breast cancer--new methods of treatment]. (2008) (1)
- Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. (2011) (1)
- Phase II study of 5-FU/LV/Irinotecan in combination with regional hyperthermia (RHT) in 5-FU/LV refractory patients with advanced colorectal cancer (2005) (1)
- Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC) (2008) (1)
- Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy. (2017) (1)
- [Medicinal therapy of metastasized neuroendocrine tumors of the gastroenteropancreatic system.] (2012) (1)
- Abstract 1342: Polymorphisms in genes involved in mitophagy pathway predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE3 phase III trials (2019) (1)
- Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial (2022) (1)
- Using data from the SIRFLOX study to evaluate depth of response within a volumetric model in patients with metastatic colorectal cancer (2017) (1)
- Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board (2023) (1)
- Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. (2021) (1)
- Expression of Indoleamine 2,3-dioxygenase in erlotinib-treated patients with advanced pancreatic cancer: Translational results from a multi-center, randomized phase III trial (2019) (1)
- Multimodale Therapiekonzepte beim metastasierten Mammakarzinom (2010) (1)
- Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells: A Phase-I clinical study (2016) (1)
- CEA und CA15-3 beim fortgeschrittenen Mammakarzinom / CEA and CA 15-3 during disease progression in metastatic breast cancer (2007) (1)
- Age and the biology of acute myeloid leukemia (1992) (1)
- Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems (2012) (1)
- Kinetics of CEA and CA15-3 correlate with response in patients undergoing chemotherapy for metastatic breast cancer (2007) (1)
- [Use of tumor markers as screening tools - sense or nonsense?]. (2015) (1)
- Histopathologic Regression and Survival in RAS Wildtype Metastatic Colorectal Cancer Under First-Line Treatment – Subgroup Analysis of the VOLFI Trial (AIO-KRK-0109) (2021) (1)
- Optimizing the Analytical Value of Oncology-Related Data Based on an In-Memory Analysis Layer: Development and Assessment of the Munich Online Comprehensive Cancer Analysis Platform (2020) (1)
- A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2014) (1)
- Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial (2022) (1)
- PO103 IMPROVING PALLIATIVE CARE IN CLINICAL ROUTINE: IN-HOUSE TRAINING OF PALLIATIVE MEDICINE AND ITS EFFECTS AND EVALUATION IN A BREAST AND GYNECOLOGICAL CENTER OF A CCC (2013) (1)
- Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine (1993) (1)
- Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research (2017) (1)
- Relevance of tumor boards for the inclusion of patients in oncological clinical trials. (2023) (0)
- Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. (2019) (0)
- Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306). (2016) (0)
- Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO- (2019) (0)
- Pancreas Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla (2015) (0)
- Assessment of Metastatic Colorectal Cancer Patients' Preferences for Biologic Treatments in Germany Using a Discrete Choice Experiment. (2021) (0)
- Adjuvante Chemotherapie des Pankreaskarzinoms mit Gemcitabin (2011) (0)
- Original Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer (2005) (0)
- Intermediate-Dose Cytosine Arabinoside and Amsacrine for Remission Induction and High-Dose Cytosine Arabinoside and Amsacrine for Intensive Consolidation in Relapsed and Refractory Adult Acute Myelogenous Leukemia (1993) (0)
- Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials (2022) (0)
- RP101 improves the efficacy of gemcitabine in treating pancreatic carcinoma. (2006) (0)
- Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). (2023) (0)
- Early Tumor Shrinkage (ETS) For the Prediction of Efficacy in Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis from an Irinotecan-Based Randomized First-Line Trial (2012) (0)
- Increased Cathepsin D expression has a negative prognostic effect on survival in gemcitabine treated patients with pancreatic ductal adenocarcinoma (2018) (0)
- Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab. (2014) (0)
- Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy. (2017) (0)
- Nintedanib plus mFOLFOX6 as second‐line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo‐controlled, phase II TRICC‐C study (AIO‐KRK‐0111) (2020) (0)
- 615: Cell-based biopharmaceuticals in a Phase I/II trial (TREAT-ME 1) for targeted drug- and gene delivery as an innovative treatment modality in advanced cancer (2014) (0)
- Prognostischer Nutzen der präoperativen Serum-Tumormarker CEA und CA 19 – 9 nach Resektion des Papillenkarzinoms unter der Berücksichtigung der Subklassifikation in pankreatobiliären und intestinalen Subtyp (2016) (0)
- SO-16 FIRE-4 (AIO-KRK-0114): Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab – secondary endpoint (2022) (0)
- [Importance of neoadjuvant chemotherapy in gastrointestinal tumors. A new standard?]. (2007) (0)
- Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): A FIRE-3 analysis. (2018) (0)
- Stand und Perspektiven der Chemotherapie beim anthrazyklinvorbehandelten Mammakarzinom – Ergebnisse randomisierter Studien (2003) (0)
- Risiken und Nutzen einer Hormonersatztherapie bei postmenopausalen Frauen (2003) (0)
- [Chemotherapy and immunotherapy of metastasized breast carcinoma]. (2002) (0)
- Panel-guided personalized medicine in metastatic breast and gynecological cancer: First experiences at the Comprehensive Cancer Centre Munich and clinical relevant changes over time (2020) (0)
- TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO. (2018) (0)
- [Actual achievements in the therapy of hepatic metastases in patients with colorectal cancer]. (2009) (0)
- LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial (2012) (0)
- Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212). (2023) (0)
- 443TiP Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7, AIO-KRK-0120) (2022) (0)
- Preisverleihungen: Poster- und Promotionspreise 2016 (2016) (0)
- ‘Above All: We Want to Live, and Hope for Cure' (2010) (0)
- Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR). (2016) (0)
- MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress. (2023) (0)
- Cathepsin D expression mediates gemcitabine resistance in pancreatic cancer (2019) (0)
- A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2012) (0)
- Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. (2017) (0)
- Development of prognostic models in non-small cell lung cancer based on 60 serum markers and clinical variables (2007) (0)
- Prognostic relevance of 46 clinical, “classical” laboratory and oncological parameters in patients with advanced non-small cell lung cancer (2005) (0)
- [Bronchial cancer: new cell biology knowledge with relevance for diagnosis and therapy. A short review]. (1985) (0)
- Zweitlinientherapie mit Ramucirumab plus Irinotecan, 5-Fluorouracil und Folinsäure (FOLFIRI) bei metastasiertem Kolorektalkarzinom (mCRC) nach Progression mit Bevacizumab plus Oxaliplatin und Fluoropyrimidin: Ergebnisse der randomisierten, plazebokontrollierten Phase-III-Doppelblindstudie RAISE (2016) (0)
- Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC). (2019) (0)
- Metastasierendes Mammakarzinom — Freie Themen (2000) (0)
- PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition (2022) (0)
- Authors & Collaborators _ RAISE study (2015) (0)
- Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial (2017) (0)
- Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials. (2018) (0)
- Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only. (2023) (0)
- Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts. (2015) (0)
- Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial. (2015) (0)
- Reply (2004) (0)
- Antitumour treatment Systemic treatment of advanced pancreatic cancer (2011) (0)
- P-066S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results of a phase I study (2015) (0)
- Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance (2022) (0)
- TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. (2023) (0)
- [Metastatic breast cancer--surgical possibilities]. (2008) (0)
- Utility of tumor markers for the early detection of metastatic breast cancer (2008) (0)
- Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research (2017) (0)
- Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial (2015) (0)
- Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials (2023) (0)
- [Current treatment strategies in breast carcinoma]. (2002) (0)
- Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109) (2019) (0)
- P-063Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC) – results from the SIRFLOX study (2016) (0)
- Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab). (2022) (0)
- Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial. (2012) (0)
- Is the primary tumor location (PTL) associated with differential gene expression profiles in patients with metastatic colorectal cancer (mCRC)? Analysis of the FIRE1-trial. (2017) (0)
- High dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HPSCT) with subsequent immunotherapy in metastatic breast cancer (MBC): Final results of a phase I stud. (2004) (0)
- S3-guideline "exocrine pancreatic carcinoma" 2007 : Results of an Evidence-Based Consensus Conference (13. - 14.10.2006) (2008) (0)
- Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study. (2021) (0)
- Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI. (2015) (0)
- Abstract 5170: Linking tumor evolution and therapy response using diagnostic targeted next generation sequencing in colorectal cancer (2014) (0)
- Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983). (2019) (0)
- Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer (2016) (0)
- [Interdisciplinary oncology using pancreatic cancer as an example]. (2007) (0)
- Können neue Substanzen endlich die Prognose verbessern? - Interdisziplinäre Behandlung des Pankreaskarzinoms (2003) (0)
- Erratum (2018) (0)
- The prognostic importance of the CA19-9 tumour marker and its use as a biochemical indicator of treatment response during (chemo-) radiotherapy of locally advanced pancreatic cancer. (2004) (0)
- RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC (2021) (0)
- MS2 TREATMENT SWITCHING ANALYSES ON PATIENT-LEVEL DATA TO INFORM TRANSFERABILITY OF A TRIAL-BASED HEALTH ECONOMIC ANALYSIS IN METASTATIC COLORECTAL CANCER: A CASE STUDY USING PATIENT-LEVEL DATA FROM THE FIRE-3 TRIAL (2020) (0)
- Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-II-Studie zur adjuvanten Immuntherapie mit Tecemotid (L-BLP25) nach R0/R1 Resektion von Lebermetastasen beim kolorektalen Karzinom (LICC): Finale Ergebnisse (2019) (0)
- A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2013) (0)
- Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212). (2023) (0)
- Cetuximab-induced skin rash: A molecular map relating polymorphisms, cell-adhesion, and autoimmunity. (2015) (0)
- The histone deacetylase complex as a drugable target in colorectal cancer. (2015) (0)
- FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer (2022) (0)
- Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). (2022) (0)
- Prospective multicenter randomized phase III studies of weekly vs standard docetaxel (D2) plus doxorubicin (D4) for 1st line treatment of metastatic breast cancer (MBC) (2004) (0)
- AIO-FIRE-8-Studie (AIO‑KRK/YMO‑0519) (2021) (0)
- TOPIC HIGHLIGHT (2014) (0)
- Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials. (2018) (0)
- 6115 POSTER Modelling Tumour Kinetics Including Early Response, Tumour Nadir and Progression During First-line Chemotherapy of Metastatic Colorectal Cancer (mCRC) (2011) (0)
- TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells: Clinical results of a phase I study. (2015) (0)
- IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial (2017) (0)
- Interdisciplinary Treatment of Colorectal Cancer (2016) (0)
- Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. (2016) (0)
- Kombinierte hepatische und extrahepatische UDP-Glukuronosyltransferase Polymorphismen prädisponieren für Leukopenie und Dosisreduktion unter Irinotecan-Therapie (2006) (0)
- Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. (2020) (0)
- Polymorphisms of pluripotency transcription factors for predicting cetuximab efficacy in metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. (2021) (0)
- Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). (2020) (0)
- Impact of polymorphisms within genes involved in regulating DNA methylation in metastatic colorectal cancer patients enrolled in three independent, randomized, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC, and FIRE-3. pathways on outcomes in (2019) (0)
- P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC) (2022) (0)
- Gentechnisch modifizierte mesenchymale Stromazellen (MSC) zur Behandlung fortgeschrittener Adenokarzinome – vom präklinischen Konzept zur klinischen Phase I/II Studie (2018) (0)
- Treatment of Mediastinal Endometrial Carcinoma Developed from Extragenital Endometriosis and Simultaneous Rectal Adenocarcinoma in a 55-year-old Woman (2023) (0)
- Profiling of differentially expressed genes in right and left side mCRC patients using nCounter customized gene expression assay. (2015) (0)
- Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab. (2016) (0)
- EP-1083 ADJUVANT RADIOCHEMOTHERAPY IN CHOLANGIOCARCINOMA MAY IMPROVE OVERALL SURVIVAL AFTER SURGERY (2012) (0)
- Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study (2017) (0)
- Genetic variants involved in bromodomain-containing protein 4 (BRD4) regulating pathway to predict outcomes in patients with metastatic colorectal cancer: Results from FIRE3 and MAVERICC trials. (2020) (0)
- This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B (2019) (0)
- Alterations in peripheral T cell subsets, T cell activation markers and immune checkpoint molecules in advanced pancreatic cancer patients receiving FOLFIRINOX or gemcitabine + nab-paclitaxel. (2018) (0)
- Antibodies for Treatment of Metastatic Colorectal Cancer (2017) (0)
- AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab. (2014) (0)
- Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. (2017) (0)
- Systemic treatment of metastatic pancreatic cancer : current standards and perspectives (2019) (0)
- [Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial]. (2020) (0)
- [Oncology 2008]. (2008) (0)
- Weekly versus 3-weekly docetaxel (D2) plus doxorubicin (D4) for first-line treatment of metastatic breast cancer (MBC). (2016) (0)
- [Pancytopenia following non-A, non-B hepatitis]. (1992) (0)
- A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results. (2019) (0)
- Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy (2022) (0)
- Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahr (2004) (0)
- Nebenwirkungsarm und doch effektiv - Endokrine Therapie des metastasierten Mammakarzinoms (2003) (0)
- Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1) (2016) (0)
- Abstract 3605: Next generation sequencing from cerebral spine fluid yields actionable targets in leptomeningeal carcinomatosis (2018) (0)
- Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal (2022) (0)
- Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database. (2016) (0)
- Ganzkörper-MRT zur frühen Rezidiverkennung bei Mamma-Ca–Patientinnen mit pathologischem Tumormarkeranstieg (2010) (0)
- Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3. (2019) (0)
- 10 Primary Advanced Unresectable Pancreatic Cancer (0)
- Follow-up for breast cancer: Results of a patients survey (2007) (0)
- Title Page / Contents Vol. 5, Supplement 1, April 2010 (2010) (0)
- Author's reply to: “Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group” (2013) (0)
- Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study. (2020) (0)
- Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110). (2021) (0)
- Future perspectives in the treatment of pancreatic cancer (2008) (0)
- BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI. (2022) (0)
- 85MO Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH) (2020) (0)
- First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). (2022) (0)
- The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy. (2018) (0)
- [Medical-oncological aspects in the treatment of pancreatic cancer]. (2009) (0)
- Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. (2018) (0)
- Regressionsgrad und Tumormarkerverlauf nach intensivierter neoadjuvanter Chemotherapie beim Kardia- und Magenkarzinom (2018) (0)
- Epoetin alfa in der Onkologie – aktuelle Entwicklungen (2003) (0)
- Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems (2013) (0)
- Erlotinib plus Gemcitabin als Therapie bei Patienten mit metastasiertem Pankreaskarzinom: Ergebnisse einer nicht-interventionellen Studie (2020) (0)
- Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program (2021) (0)
- Wann sind die neuen Therapieregime indiziert? - Moderne Ansätze in der Behandlung des metastasierten kolorektalen Karzinoms (2003) (0)
- Evidenz der adjuvanten Chemotherapie beim Pankreaskarzinom (2013) (0)
- Prädiktion des Therapieansprechens beim kolorektalen Karzinom im multizellulären Sphäroidmodell: Sphero-PCT-Studie (2008) (0)
- Algorithmen zur Behandlung des Pankreaskarzinoms (2019) (0)
- Stellenwert und qualitative Voraussetzungen der Magnetresonanztomographie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom – interdisziplinäre Empfehlungen (2020) (0)
- Aktuelle Versorgungslage der chemotherapeutischen Versorgung von Patientinnen mit metastasiertem Mammakarzinom in Deutschland – Eine Umfrage der Organkommission Mamma der AGO (2015) (0)
- HER-2/neu im Gewebe und Blut zum Zeitpunkt der Primärdiagnose des Mammakarzinoms (2008) (0)
- Mit Biologicals näher am Ziel (2008) (0)
- Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study. (2016) (0)
- Neuroendokrine Karzinome (NEC) von Dünndarm und Pankreas – Biotherapie, Chemotherapie und neue medikamentöse Therapieansätze (2009) (0)
- Moderne adjuvante Chemotherapie und Nachsorge (2012) (0)
- Molekular-basierte Therapiekonzepte beim fortgeschrittenen Pankreaskarzinom (2007) (0)
- Aera zu Ende: Zehn Jahre RoLa zwischen Dresden und Lobositz. Die Verkehrssituation von 1994 / Gone: ten years of intermodal service between Dresden and Lobositz (2005) (0)
- Individualisierte Therapie des fortgeschrittenen Schilddrüsenkarzinoms (2015) (0)
- Im Fokus: Tumoren des Dickdarms (2011) (0)
- Neoadjuvante und adjuvante Therapien bei soliden Tumoren : Bessere OP-Ergebnisse, geringere Rezidivrisiken (2007) (0)
- Prognostischer Wert des präoperativen CEA und CA 19-9 bei der Resektion des Papillenkarzinoms unter der Berücksichtigung der Subklassifikation in pankreatobiliären und intestinalen Typ (2015) (0)
- S 3-Leitlinie zum exokrinen Pankreaskarzinom S 3-Guideline Exocrine Pancreatic Cancer (2013) (0)
- Chemotherapie und systemische Therapie bei Lebermetastasen (2010) (0)
- Die neoadjuvante und adjuvante Therapie des resektablen Kolonkarzinoms: Aktuelle Standards und Entwicklungen (2021) (0)
- Differenziertes Schilddrüsenkarzinom: Radioiod-refraktäre Tumoren mit neuen Optionen (2015) (0)
- Adjuvante und palliative Therapie des Pankreaskarzinoms (2004) (0)
- Überleben nach sekundärer Resektion von Lebermetastasen beim metastasierten kolorektalen Karzinom: Eine vergleichende Analyse der LICC-Studie mit historischen Kontrollen (CELIM, FIRE-3) (2019) (0)
- Personalisierte Medizin bei metastasierten Brust- und gynäkologischen Krebserkrankungen. Erste Ergebnisse in CCC LMU München (2020) (0)
- Die Auswirkungen der COVID-19-Pandemie aus der Sicht ambulanter Krebspatienten (2022) (0)
- Diagnostik und Therapie beim Rezidiv des Pankreaskarzinoms (2013) (0)
- Band 25, Heft 1, Februar 2002 (2002) (0)
- Wann bringt die Operation zusätzliche Vorteile? (2016) (0)
- Therapie des kolorektalen Karzinoms mit gegen den EGF-Rezeptor gerichteten Antikörpern (2010) (0)
- mFOLFOXIRI+Panitumumab versus FOLFOXIRI als Erstlinientherapie bei Patienten mit RAS-Wildtyp metastasiertem KRK: die randomisierte VOLFI-Studie der AIO (KRK0109) (2018) (0)
- Contents Vol. 73, 2007 (2008) (0)
- Deutsche Fatigue Gesellschaft e.V. (DFaG) / Arbeitsgemeinschaft GynäkologischeOnkologie e.V. (AGO) Organkommission Ovar (2003) (0)
- Therapie des metastasierten Pankreaskarzinoms (2022) (0)
- Das metastasierte kolorektale Karzinom – Eine Analyse der Behandlungsmodalitäten und Überlebenszeiten gestern und heute (2014) (0)
- Vitamine und Spurenelemente in der Onkologie (2018) (0)
- Neue Therapiestrategien beim metastasierten Mammakarzinom : Mit Biologicals näher am Ziel (2008) (0)
- Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie (2022) (0)
- Lebermetastasen beim kolorektalen Karzinom : Resektion, Chemotherapie oder beides? (2009) (0)
- Stellenwert einer neoadjuvanten Chemotherapie bei gastrointestinalen Tumoren (2007) (0)
- Vitamine und Spurenelemente in der Onkologie (2017) (0)
- Gemcitabine-Mediated Enhancement of Cellular Cytarabine-5′-Triphosphate (ara-CTP) Accumulation (1998) (0)
- Wahl der Behandlungsstrategie auf der Basis molekularer Marker (2015) (0)
- CRC: Lokalisation des Primarius von Bedeutung (2016) (0)
- Aktuelle Therapiekonzepte für primär resektable und lokal fortgeschrittene Pankreaskarzinome (2015) (0)
- Management von Lebermetastasen (2007) (0)
- Interdisziplinäre Onkologie am Beispiel des Pankreaskarzinoms (2007) (0)
- Palliativmedizinische Versorgung in der klinischen Routine: Inhouse Schulung Palliativmedizin der Frauenklinik (Brustzentrum und Gynäkologisches Krebszentrum) durch das Interdisziplinäre Palliativzentrum als interdisziplinäre und sektorübergreifende Weiterbildungsmaßnahme am Beispiel des Klinikums d (2013) (0)
- Impfkommission ( StIKo ) die Emp-fehlung zur Impfung gegen humane Papillomviren ( HPV ) bei Mädchen in Deutschland aus , um die Krankheits-last durch HPV-assoziierte (2020) (0)
- Regionale Chemotherapie aus der Sicht des Onkologen (2010) (0)
- Systemtherapie des metastasierten Analkarzinoms (2020) (0)
- Systemische Therapie des duktalen Pankreaskarzinoms (2021) (0)
- Neue Strategien in der Krebstherapie: Was bringen Immunologie und Molekularbiologie? 1. Berliner Symposium ‘Onkologie in Bewegung’, Berlin, 9. bis 11. November 2001 (2002) (0)
- Tumormarker zur Früherkennung – sinnvoll oder sinnlos? (2015) (0)
- Perioperatives Kompliationsrisiko bei Leberresektionen bei CCC (2011) (0)
- Stellenwert monoklonaler Antikörper und oraler Tyrosinkinase-Inhibitoren in der Therapie des fortgeschrittenen Pankreaskarzinoms (2008) (0)
- Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische, multinationale Phase II-Studie zur Immuntherapie mit L-BLP25 bei Patienten mit kolorektalem Karzinom nach R0/R1-Lebermetastasenresektion (LICC) (2012) (0)
- Komplette Tumorentfernung bei Metastasierung -mehr als Palliation : Wann bringt die Operation zusätzliche Vorteile (2008) (0)
- Aktuelle Behandlungsstrategien beim Mammakarzinom (2002) (0)
- Verschlussikterus durch Pankreaskopfkarzinom: Welche Patienten profitieren noch von einer Operation? (2009) (0)
- Präzisionsonkologie und molekulare Tumorboards – Konzepte, Chancen und Herausforderungen (2018) (0)
- Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO – „past, present, and future“ (2022) (0)
- Tumormarker in der frühzeitigen Diagnostik von Fernmetastasen beim Mammakarzinom (2008) (0)
- Systemische Chemotherapie beim metastasierten Mammakarzinom (2006) (0)
- Neue Ansätze in der Therapie des metastasierten Pankreaskarzinoms (2018) (0)
- Was bringt eine neoadjuvante Chemotherapie beim Pankreaskarzinom (2013) (0)
- PD-0008 Radiofrequency Ablation (RFA) Versus Robotic Radiosurgery (RRS) in the Treatment of Unresectable Colorectal Liver Metastases (2012) (0)
- Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers (2022) (0)
- Overall survival in the FOXFIRE-SIRFLOX-FOXFIRE Global prospective randomized studies of first-line SIRT in patients with mCRC (2017) (0)
- Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study (2022) (0)
- 396P Impact of depth of response of induction therapy on consecutive maintenance therapy in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212) (2022) (0)
- Role of Deoxycytidine Triphosphate for Feedback Regulation of Deoxycytidine Kinase and Phosphorylation of Cytosine Arabinoside in Whole Leukemic Cells (1997) (0)
- Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3). (2019) (0)
- IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial. (2016) (0)
- Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study (2020) (0)
- Subject Index Vol. 72, 2007 (2008) (0)
- Highlights ASCO 2013: Kolorektale Tumoren (2013) (0)
- Are Predictions from Partin Tables and Kattan Nomograms Useful for the Assessment of the Oncological Outcomes after LDR Brachytherapy +-EBRT +- ADT in Localized (N0M0) Prostate Cancer? (2016) (0)
- EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3) (2022) (0)
- CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials. (2020) (0)
- Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity (2021) (0)
- O-0013 Improved Early Prediction of Individual Prognosis for Patients with Metastatic Colorectal Cancer: Joint Modeling of Tumor Shrinkage with Volume Data (2012) (0)
- Clinical News (2010) (0)
- Genomanalyse maligner Tumoren (2019) (0)
- MP29-17 EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (2023) (0)
- [Treatment of metastatic pancreatic cancer]. (2022) (0)
- O-014Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: results of the SIRFLOX study (2016) (0)
- SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies (2022) (0)
- Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial. (2022) (0)
- Cardiac function surveillance in patients during anti-cancer treatment: Initial experience with the CW-Doppler-based USCOM device and correlation to echocardiography and serum proBNP levels (2008) (0)
- Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective. (2023) (0)
- Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials. (2020) (0)
- Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients. (2017) (0)
- Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials. (2018) (0)
- FIRE-7-Studie (AIO-KRK-0120) (2021) (0)
- SIRFLOX study: Novel approach to define depth of response (DpR) within a volumetric model in patients with metastatic colorectal cancer (mCRC). (2016) (0)
- 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database (2020) (0)
- [Molecular-based treatment concepts in advanced pancreatic cancer]. (2007) (0)
- Cost-Effectiveness Analysis of Ugt1a1 Genotyping Before Colorectal Cancer Treatment with Irinotecan. (2014) (0)
- Vinorelbin (i.v. plus oral) in Kombination mit Trastuzumab in der Erstlinientherapie des HER-2/neu überexprimierenden, metastasierten Mammakarzinoms: Phase-II-Studie der AIO (2008) (0)
- 1688P Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment (2022) (0)
- Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer (2018) (0)
- Development of a Predictive Score Using Amphiregulin (AREG), Epiregulin (EREG) and Egfr-Fish Expression Levels to Determine Treatment Efficacy in Mcrc Patients Receiving Cetuximab-Based Therapy. Analysis of the German AIO CRC-0104 Trial (2012) (0)
- Predicting the real volume of liver metastases from diameter-based measurements and the lesions’ shape (2016) (0)
- [Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer]. (2003) (0)
- Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database. (2018) (0)
- Prediction of the therapeutic response in colorectal cancer patients using the Spheroid Microtumor Technology (2008) (0)
- Longterm Results 60 Months after LDR-Brachytherapy +-EBRT+-ADT for Non-Metastasized Prostate Cancer with Low, Intermediate and High Progression Risk - Evaluation for Various Risk Group Systems, I-PSA, I-Gleason and I-Stage (2016) (0)
- PROJECTION-Studie (2021) (0)
- 477 pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial (2012) (0)
- Regulation of deoxyctidine kinase by deoxyctidine and deoxyctidine-5′ triphosphate in whole cells (1997) (0)
- FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer (2022) (0)
- Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306 (2022) (0)
- PD-0021 Hand-Foot-Syndrome (HFS) is a Clinical Predictor of Survival in Capecitabine Treated Patients (PTS) with Colorectal Cancer (2012) (0)
- Safety and quality-of-life in patients treated with aflibercept and FOLFIRI as 2nd line treatment for their metastatic colorectal cancer (mCRC) - a German subgroup analysis of the Aflibercept Safety and Quality-of-Life Program (ASQoP) (2017) (0)
- Prognostischer Wert der CT attenuation von Lebermetastasen des metastasierten kolorektalen Karzinoms für das overall survival (2018) (0)
- Individualized management of Aggressive Angiomyxoma: A case report (2014) (0)
- 441P Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study (2020) (0)
- Involvement of ICE-Like Proteases in Gemcitabine-Induced Programmed Cell Death (1998) (0)
- Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial. (2020) (0)
- Altersdifferenzierte Therapie maligner Erkrankungen (2000) (0)
- Contents Vol. 72, 2007 (2008) (0)
- Divergierende Morbidität und Mortalität nach Leberresektion für Cholangiokarzinom (2014) (0)
- Panel-guided personalized medicine in metastatic breast and gynecological cancer: First experiences at the CCC Munich and clinically relevant changes over time (2020) (0)
- Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation. (2022) (0)
- Pattern of S100-release in benign and malignant diseases beside malignant melanoma/Freisetzung von S100 bei benignen und malignen Erkrankungen jenseits des malignen Melanoms (2013) (0)
- Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials (2019) (0)
- Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials. (2021) (0)
- [Not Available]. (2011) (0)
- Treatment until progression: Data of the "on-treatment" population of the FIRE-3 (AIO KRK-0306) study. (2015) (0)
- Current adjuvant and neoadjuvant treatment concepts in pancreatic cancer (2009) (0)
- Subject Index Vol. 73, 2007 (2008) (0)
- Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort. (2016) (0)
- colorectal cancer 324O SINGLE-AGENT CETUXIMAB AS FIRST-LINE TREATMENT FOR ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER. PRELIMINARY RESULTS OF A TTD PHASE II STUDY (2006) (0)
- [Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study]. (2003) (0)
- [Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations]. (2020) (0)
- Qualitätsmanagement und Zertifizierung in der Onkologie. Bericht vom DGHO-Symposium anlässlich der DGHO-Jahrestagung am 30.09.2001 in Mannheim (2002) (0)
- Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials. (2019) (0)
- Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306). (2019) (0)
- Advances in cancer immunotherapy 2019 – latest trends (2019) (0)
- Department of Error (2006) (0)
- Her2/neu as a promising biomarker to stratify CRC patients with liver metastasis for trastuzumab treatment. (2015) (0)
- Robotic radiosurgery of liver metastases of solid tumors. (2016) (0)
- Computed Tomography Image-Based Deep Survival Regression for Metastatic Colorectal Cancer Using a Non-proportional Hazards Model (2019) (0)
- A double-blind, randomized placebo-controlled, phase II study of maintenance enzastaurin (ENZ) with 5-FU/leucovorin (LV) plus bevacizumab (BV) following first-line therapy for metastatic colorectal cancer (mCRC). (2011) (0)
- Publisher Correction: The Technome - A Predictive Internal Calibration Approach for Quantitative Imaging Biomarker Research (2020) (0)
- Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109). (2019) (0)
- Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial (2015) (0)
- Evidenz der Chemotherapie beim fortgeschrittenen Pankreaskarzinom (2013) (0)
- FIRE-5-Studie (AIO TF-0118) (2019) (0)
- Combination of antiangiogenic therapy using the mTOR inhibitor RAD001 (everolimus) and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: Dose-finding study. (2012) (0)
- Reply to "Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?" by Evesque et al. (2020) (0)
- Tumor assessments according to RECIST versus volumetry: Impact on early changes in tumor size in metastatic colorectal cancer (mCRC). (2012) (0)
- Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114) (2019) (0)
- Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO (2017) (0)
- Analysis of prognostic factors for 60-day mortality: Evaluation of a randomized phase III trial investigating FUFIRI versus mIROX as first-line treatment of metastatic colorectal cancer (mCRC). (2010) (0)
- Reply to: The definition of locally advanced pancreatic cancer (2010) (0)
- Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab). (2016) (0)
- Ob alt oder jung - Signifikanter Zugewinn an Überlebenszeit (2010) (0)
- Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. (2023) (0)
- Serum amyloid α (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. (2016) (0)
- Enhanced Accumulation of dFdC-Triphosphate in Tumor Cells with Short Retention of ARA -C Triphosphate (1992) (0)
- Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis. (2023) (0)
- [Current progress in therapy of malignant diseases]. (2005) (0)
- The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: In reply (2009) (0)
- Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials. (2021) (0)
- 424P Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118) (2022) (0)
- Impact of exact segment by segment primary tumor location status on anti-EGFR antibody first-line treatment efficacy in RAS/BRAF wild-type and BRAF mutant metastatic colorectal cancer. A pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. (2021) (0)
- The SpheroPCT study: The spheroid microtumor model is predictive for the therapeutic response of colorectal cancers (2008) (0)
- Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. (2019) (0)
- Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. (2019) (0)
- Busulfan Pharmacology in Bone Marrow Transplantation Patients (1997) (0)
- Early detection of tumor recurrence in patients with asymptomatic breast cancer with tumor marker kinetics and whole body imaging. (2011) (0)
- Internal radiation more effective in patients with larger metastatic colorectal liver tumour burden (2016) (0)
- SIRFLOX: Differences in site of first progression between mFOLFOX6 +/- bevacizumab (bev) versus mFOLFOX6 +/- bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC). (2016) (0)
- High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3. (2020) (0)
- Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial). (2019) (0)
- 1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116) (2022) (0)
- Inhibitory Effect of 2′,2′-Difluorodeoxycytidine on Cytidine 5′-Triphosphate Synthetase (1994) (0)
- Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’” [European Journal of Cancer 135 (2020) 1-7] (2021) (0)
- Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial. (2018) (0)
- Empirische Bestimmung volumetrischer Grenzwerte gemäß RECIST 1.1 zur Beurteilung des Therapieansprechens bei Lebermetastasen (2017) (0)
- Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study (2021) (0)
- A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3. (2018) (0)
- The predictive role of CA 19-9 kinetics for time-to-progression (TTP) and overall survival (OS) in patients receiving palliative first-line chemotherapy for advanced pancreatic cancer. (2009) (0)
- Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study). (2021) (0)
- Cetuximab or bevacizumab in metastatic colorectal cancer (2014) (0)
- Strategies inPrevention ofInvasive Pulmonary Aspergillosis in Immunosuppressed orNeutropenic Patients (1994) (0)
- 2,2′-Difluorodeoxycytidine: A New Antimetabolite with Inhibitory Activity Against Ribonucleotide Reduction dCMP Deaminase (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Volker Heinemann?
Volker Heinemann is affiliated with the following schools:
